| 1. |
Schoener L, Jellinghaus S, Richter B, et al. Reversal of the platelet inhibitory effect of the P2Y<sub>12</sub> inhibitors clopidogrel, prasugrel, and ticagrelor <italic>in vitro</italic>: a new approach to an old issue. Clin Res Cardiol, 2017(2): 1-7.
|
| 2. |
Pelletier-Galarneau M, Hunter CRRN, Ascah KJ, et al. Randomized trial comparing the effects of ticagrelor <italic>versus</italic> clopidogrel on myocardial perfusion in patients with coronary artery disease. J Am Heart Assoc, 2017, 6(5): e005894.
|
| 3. |
Rollini F, Franchi F, Thano E, et al. <italic>In vitro</italic> pharmacodynamic effects of cangrelor on platelet P2Y<sub>12</sub> receptor-mediated signaling in ticagrelor-treated patients. JACC Cardiovasc Interv, 2017, 10(13): 1374-1375.
|
| 4. |
Roshammar D, Bergstrand M, Andersson TA, et al. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction. Int J Clin Pharmacol Ther, 2017, 55(5): 416-424.
|
| 5. |
Peng JB, Wang YC, Li MP, et al. An HPLC-MS/MS method for the quantitative determination of ticagrelor and its active metabolite AR-C124910XX in human plasma and its application to a clinical study. Current Pharmaceutical Analysis, 2017, 13(3): 296-303.
|
| 6. |
Fromonot J, Dignat-Georges F, Rossi P, et al. Ticagrelor improves peripheral arterial function in acute coronary syndrome patients: relationship with adenosine plasma level. J Am Coll Cardiol, 2016, 67(16): 1967-1968.
|
| 7. |
Guimar?es LF, Stone GW, Caixeta A. Reply: delayed onset of novel P2Y<sub>12</sub> receptor antagonists action post fibrinolysis. Int J Cardiol, 2017, 234: 132.
|
| 8. |
James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y<sub>12</sub> receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J, 2009, 157(4): 599-605.
|
| 9. |
Vercellino M, Sanchez FA, Boasi VA, et al. Ticagrelor <italic>versus</italic> clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis. BMC Cardiovasc Disord, 2017, 17(1): 97.
|
| 10. |
Xu LX, Chen KY, Liu T, et al. GW27-e0058 Comparisons of loading doses of ticagrelor <italic>versus</italic> clopidogrel in preventing periprocedural myocardial infarction. J Am Coll Cardiol, 2016, 68(16): C89-C90.
|
| 11. |
Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol, 2010, 56(3): 185-193.
|
| 12. |
Zafar M, Mehremic S, Koloffon CL, et al. Variability of antiplatelet effect with ticagrelor <italic>versus</italic> clopidogrel in diabetic patients. J Am Coll Cardiol, 2016, 67(13): 455.
|
| 13. |
Huynh K. Antiplatelet therapy: ticagrelor reduces cardiac events in patients with PAD or diabetes. Nat Rev Cardiol, 2016, 13(6): 310-311.
|
| 14. |
Sweeny JM, Angiolillo DJ, Franchi F, et al. Impact of diabetes mellitus on the pharmacodynamic effects of ticagrelor <italic>versus</italic> clopidogrel in troponin-negative acute coronary syndrome patients undergoing ad-hoc percutaneous coronary intervention. J Am Heart Assoc, 2017, 6(4): e005650.
|
| 15. |
Bellavia A, Wallentin L, Orsini N, et al. Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart, 2017, 4(2): e000557.
|
| 16. |
Scirica BM, Cannon CP, Emanuelsson H, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial results of the continuous electrocardiogra. J Am Coll Cardiol, 2011, 57(19): 1908-1916.
|
| 17. |
Nicol M, Deblaise J, Choussat R, et al. Side effects of ticagrelor: sinus node dysfunction with ventricular pause. Int J Cardiol, 2015, 191: 56-57.
|
| 18. |
Goldberg A, Rosenfeld I, Nordkin I, et al. Life-threatening complete atrioventricular block associated with ticagrelor therapy. Int J Cardiol, 2015, 182: 379-380.
|
| 19. |
Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol, 2013, 61(7): 723-727.
|
| 20. |
Mediero A, Wilder T, Reddy VS, et al. Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation <italic>in vivo</italic> via an adenosine-dependent mechanism. FASEB J, 2016, 30(11): 3887-3900.
|
| 21. |
Birnbaum Y, Birnbaum GD, Birnbaum I, et al. Ticagrelor and rosuvastatin have additive cardioprotective effects via adenosine. Cardiovasc Drugs Ther, 2016, 30(6): 539-550.
|
| 22. |
Casadonte L, Marques KM, Spaan JA, et al. Temporal dissociation between the minimal distal-to-aortic pressure ratio and peak hyperemia during intravenous adenosine infusion. Am J Physiol Heart Circ Physiol, 2017, 312(5): H992-H1001.
|
| 23. |
Bortoluzzi A, Vincenzi F, Govoni M, et al. A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther, 2016, 18: 192.
|
| 24. |
Monfredi O, Tsutsui K, Sirenko S, et al. Pacemaker clocks become uncoupled to cause asystole: heart’s endgame. Europace, 2017, 19(Suppl 3): iii339-iii340.
|
| 25. |
Muntean DM, Kiss L, Jost N, et al. ATP-sensitive Potassium Channel modulators and cardiac arrhythmias: an update. Curr Pharm Des, 2015, 21(8): 1091-1102.
|
| 26. |
Li XY, Wang QB, Xue Y, et al. Ticagrelor compared with clopidogrel increased adenosine and cyclic adenosine monophosphate plasma concentration in acute coronary syndrome patients. Basic Clin Pharmacol Toxicol, 2017, 120(6): 610-614.
|
| 27. |
Li X, Wang Q, Xue Y, et al. Ticagrelor increased adenosine and cyclic adenosine monophosphate plasma concentration compared with clopidogrel in acute coronary syndromes patients. Basic Clin Pharmacol Toxicol, 2017, 120(6): 610-614.
|
| 28. |
Bae JS, Jang JS. Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease:a meta-analysis. Heart Vessels, 2016, 31(3): 275-287.
|
| 29. |
Ozturk C, Unlu M, Yildirim AO, et al. The progressed atrioventricular block associated with ticagrelor therapy may not require permanent pacemaker after acute coronary syndrome; it may be reversible. Int J Cardiol, 2016, 203: 822-824.
|
| 30. |
Unlu M, Demirkol S, Yildirim AO, et al. Atrioventricular block associated with ticagrelor therapy may require permanent pacemaker. Int J Cardiol, 2016, 202: 946-947.
|
